Bispecific antibodies (bsAbs) are antibodies that have two distinct binding domains, which can bind to two antigens or two epitopes (an antigen part) of the same antigen simultaneously (2). BsAb ...

Bispecific antibodies represent an innovative paradigm in cancer therapy ... Lastly, the pharmacokinetics (PK) and pharmacodynamics (PD) of these prodrugs must be meticulously regulated. Optimizing ...

prompting the creation of multispecific antibodies, which include bispecific, trispecific, and tetraspecific antibodies. Among these, bispecific antibodies, capable of binding to two distinct epitopes ...

NEW YORK – Context Therapeutics on Wednesday said it began treating patients in a Phase I trial of its claudin 6 (CLDN6)- and CD3 T-cell-engaging bispecific antibody, CTIM-76, in CLDN6-positive ...

Orion Corporation (“Orion”) and Invenra Inc. (“Invenra”), an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in ...

Jeffrey V. Matous, MD, discusses how best practices in transitioning care between academic and community centers can enhance patient outcomes when receiving bispecific antibodies, and the critical ...

SAN DIEGO — In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of bispecific antibodies for lymphoma presented at ASH Annual ...

Experts said a certain type of bispecific antibody seems to have hit upon a crucial combination of two cancer targets: the proteins VEGF and either PD-1 or PD-L1. “It’s exactly that,” said ...

Zenocutuzumab is a novel bispecific antibody designed by Merus, N.V. In a multicenter global phase 2 clinical trial led by MSK gynecologic medical oncologist and early drug development specialist ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific antibody originating from China’s ...

NR- not reported NR*- not reached Clinical outcome data with use of bispecific antibodies.